Yale and IsoPlexis worked together to measure checkpoint inhibitor biomarkers by applying T-Cell cytokine secretomics to cancer immunology. IsoPlexis technology found novel single-cell predictive biomarkers for response in TILs (tumor infiltrating lymphocytes) of checkpoint inhibitor (PD-1) patients.
Caltech and UCLA
Caltech and UCLA used IsoCode (SCBC) to apply cancer phospho-signaling to treating glioblastoma. SCBC displayed better signaling pathway detection than genomics, improving patient outcomes in glioblastoma pre-clinical models through improved, single-cell, pathway specific drug targeting.
MSKCC and Yale
Memorial Sloan Kettering and Yale used IsoCode (SCBC) to apply cancer secretomics to treating inflammation in myelofibrosis. SCBC showed the ability to detect important inflammatory cell subsets in pre-clinical models and myelofibrosis stages, non-invasively in patients.
Collaborate with Us
IsoPlexis technology can offer breakthrough clinical insights and enable improved targeting of complex treatments to the patients who need them most.